Trial Profile
A Phase II Study to Determine the Pathological Complete Response Rate and Immunomodulatory Effects of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast Cancer
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Bavituximab (Primary) ; Paclitaxel
- Indications Advanced breast cancer; Early breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- Sponsors Peregrine Pharmaceuticals
- 08 Mar 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 12 Feb 2016 Status changed from planning to not yet recruiting as per ClinicalTrials.gov record.
- 13 Jan 2016 New trial record